[Clinical value of changes of SUVmax in series18F-FDG PET/CT imaging before and after chemotherapy for non-small cell lung cancer].
Objective:To evaluate the clinical value of changes of maximum standardized uptake value (SUVmax) in series18F-FDG PET/CT imaging before and after chemotherapy for non-small cell lung cancer.Methods:From July 2008 to July 2014, a total of 18 patients with pathological confirmed advanced NSCLC who received systemic chemotherapy were enrolled.18F-FDG PET/CT scans were performed before, 3-4 weeks after 2-4 cycles chemotherapy, 3-4 weeks after the end of chemotherapy for all patients, and added fourth scan for 3 patients 1 year later.The SUVmax of region of interesting was calculated.The histological diagnosis or clinical findings in a 36 months follow-up period served as the standard of control.Results:New metastases foci were found by18F-FDG PET/CT scans before chemotherapy in 7 of 18 patients.The plans of chemotherapy for 5 patients were changed as therapeutic responses were evaluated according to changes of SUVmax.Targeted therapy was added for 2 patients after the end of chemotherapy.There was a statistically significant difference in outcome of survival analysis between patients performed PET/CT scans and non-performed (P<0.05).Conclusion:Changes of SUVmax in series18F-FDG PET/CT imaging before and after chemotherapy could be used to evaluate therapeutic response and effectively predict survival in patients with advanced NSCLC.
*Department of Oncology, First Affiliated Hospital of Soochow University, Suzhou 215006, China.
N
N
Yin
Z X
ZX
Wang
Y B
YB
Zhu
J
J
Xie
S M
SM
Deng
B
B
Zhang
Y W
YW
Wu
D000970:Antineoplastic Agents; D002289:Carcinoma, Non-Small-Cell Lung; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms; D000072078:Positron Emission Tomography Computed Tomography; D016019:Survival Analysis
D000970:Antineoplastic Agents; D019788:Fluorodeoxyglucose F18